243 related articles for article (PubMed ID: 9816007)
41. Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma.
Bennouna J; Bompas E; Neidhardt EM; Rolland F; Philip I; Galéa C; Salot S; Saiagh S; Audrain M; Rimbert M; Lafaye-de Micheaux S; Tiollier J; Négrier S
Cancer Immunol Immunother; 2008 Nov; 57(11):1599-609. PubMed ID: 18301889
[TBL] [Abstract][Full Text] [Related]
42. In vivo blockade of TNF-alpha by intravenous infusion of a chimeric monoclonal TNF-alpha antibody in patients with rheumatoid arthritis. Short term cellular and molecular effects.
Lorenz HM; Antoni C; Valerius T; Repp R; Grünke M; Schwerdtner N; Nüsslein H; Woody J; Kalden JR; Manger B
J Immunol; 1996 Feb; 156(4):1646-53. PubMed ID: 8568271
[TBL] [Abstract][Full Text] [Related]
43. Killing activity of human umbilical cord blood-derived TCRValpha24(+) NKT cells against normal and malignant hematological cells in vitro: a comparative study with NK cells or OKT3 activated T lymphocytes or with adult peripheral blood NKT cells.
Hagihara M; Gansuvd B; Ueda Y; Tsuchiya T; Masui A; Tazume K; Inoue H; Kato S; Hotta T
Cancer Immunol Immunother; 2002 Mar; 51(1):1-8. PubMed ID: 11845254
[TBL] [Abstract][Full Text] [Related]
44. Relation of pro- and anti-inflammatory cytokines and the production of nitric oxide in patients receiving high-dose immunotherapy with interleukin-2.
Locker GJ; Kofler J; Stoiser B; Wilfing A; Wenzel C; Wögerbauer M; Steger GG; Zielinski CC; Mader R; Burgmann H
Eur Cytokine Netw; 2000 Sep; 11(3):391-6. PubMed ID: 11022123
[TBL] [Abstract][Full Text] [Related]
45. 41.8 degrees C whole body hyperthermia as an adjunct to chemotherapy induces prolonged T cell activation in patients with various malignant diseases.
Atanackovic D; Nierhaus A; Neumeier M; Hossfeld DK; Hegewisch-Becker S
Cancer Immunol Immunother; 2002 Dec; 51(11-12):603-13. PubMed ID: 12439605
[TBL] [Abstract][Full Text] [Related]
46. A dose-escalation and pharmacokinetic study of subcutaneously administered recombinant human interleukin 12 and its biological effects in Japanese patients with advanced malignancies.
Ohno R; Yamaguchi Y; Toge T; Kinouchi T; Kotake T; Shibata M; Kiyohara Y; Ikeda S; Fukui I; Gohchi A; Sugiyama Y; Saji S; Hazama S; Oka M; Ohnishi K; Ohhashi Y; Tsukagoshi S; Taguchi T
Clin Cancer Res; 2000 Jul; 6(7):2661-9. PubMed ID: 10914707
[TBL] [Abstract][Full Text] [Related]
47. Local/regional recombinant interleukin 2 (rIL-2) immunotherapy of tumors. Intra-arterial continuous infusion of rIL-2 in bladder cancer patients: a phase I study.
Velotti F; Tubaro A; Stoppacciaro A; Pettinato A; Morrone S; Bossola P; Napolitano T; Miano L; Ruco L; Piccoli M
Ann Ist Super Sanita; 1990; 26(3-4):411-21. PubMed ID: 2091503
[TBL] [Abstract][Full Text] [Related]
48. Continuous infusion interleukin-2 and tumor-derived activated cells as treatment of advanced solid tumors: a National Biotherapy Study Group Trial.
Oldham RK; Dillman RO; Yannelli JR; Barth NM; Maleckar JR; Sferruzza A; Cohen RJ; Minor DR; Spitler L; Birch R
Mol Biother; 1991 Jun; 3(2):68-73. PubMed ID: 1910622
[TBL] [Abstract][Full Text] [Related]
49. Phase Ia trial of murine immunoglobulin A antitransferrin receptor antibody 42/6.
Brooks D; Taylor C; Dos Santos B; Linden H; Houghton A; Hecht TT; Kornfeld S; Taetle R
Clin Cancer Res; 1995 Nov; 1(11):1259-65. PubMed ID: 9815920
[TBL] [Abstract][Full Text] [Related]
50. High serum levels of soluble IL-2 receptor, cytokines, and C reactive protein correlate with impairment of T cell response in patients with advanced epithelial ovarian cancer.
Macciò A; Lai P; Santona MC; Pagliara L; Melis GB; Mantovani G
Gynecol Oncol; 1998 Jun; 69(3):248-52. PubMed ID: 9648596
[TBL] [Abstract][Full Text] [Related]
51. The effects of oral pentoxifylline on the cytokine release syndrome during inductive OKT3.
DeVault GA; Kohan DE; Nelson EW; Holman JM
Transplantation; 1994 Feb; 57(4):532-40. PubMed ID: 8116037
[TBL] [Abstract][Full Text] [Related]
52. Combination therapy with interleukin-2 and antitumor monoclonal antibodies.
Sondel PM; Hank JA
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S121-7. PubMed ID: 9457407
[TBL] [Abstract][Full Text] [Related]
53. The in vitro function of lymphocytes from 25 cancer patients receiving four to seven consecutive days of recombinant IL-2.
Rosenthal NS; Hank JA; Kohler PC; Minkoff DZ; Moore KH; Bechhofer R; Hong R; Storer B; Sondel PM
J Biol Response Mod; 1988 Apr; 7(2):123-39. PubMed ID: 3258904
[TBL] [Abstract][Full Text] [Related]
54. Local activation of immune response in bladder cancer patients treated with intraarterial infusion of recombinant interleukin-2.
Velotti F; Stoppacciaro A; Ruco L; Tubaro A; Pettinato A; Morrone S; Napolitano T; Bossola PC; Franks CR; Palmer P
Cancer Res; 1991 May; 51(9):2456-62. PubMed ID: 2015606
[TBL] [Abstract][Full Text] [Related]
55. In vivo blockade of tumor necrosis factor-alpha in patients with rheumatoid arthritis: longterm effects after repeated infusion of chimeric monoclonal antibody cA2.
Lorenz HM; Grünke M; Hieronymus T; Antoni C; Nüsslein H; Schaible TF; Manger B; Kalden JR
J Rheumatol; 2000 Feb; 27(2):304-10. PubMed ID: 10685789
[TBL] [Abstract][Full Text] [Related]
56. Depressed in vitro T cell responses concomitant with augmented interleukin-2 responses by lymphocytes from cancer patients following in vivo treatment with interleukin-2.
Hank JA; Sosman JA; Kohler PC; Bechhofer R; Storer B; Sondel PM
J Biol Response Mod; 1990 Feb; 9(1):5-14. PubMed ID: 2181071
[TBL] [Abstract][Full Text] [Related]
57. Construction and characterization of a novel fusion protein consisting of anti-CD3 antibody fused to recombinant interleukin-2.
Lee KD; Chen HW; Chen CC; Shih YC; Liu HK; Cheng ML
Oncol Rep; 2006 May; 15(5):1211-6. PubMed ID: 16596189
[TBL] [Abstract][Full Text] [Related]
58. Synergistic interleukin-18 and low-dose interleukin-2 promote regression of established murine neuroblastoma in vivo.
Redlinger RE; Mailliard RB; Lotze MT; Barksdale EM
J Pediatr Surg; 2003 Mar; 38(3):301-7; discussion 301-7. PubMed ID: 12632339
[TBL] [Abstract][Full Text] [Related]
59. Phase I study of bromohydrin pyrophosphate (BrHPP, IPH 1101), a Vgamma9Vdelta2 T lymphocyte agonist in patients with solid tumors.
Bennouna J; Levy V; Sicard H; Senellart H; Audrain M; Hiret S; Rolland F; Bruzzoni-Giovanelli H; Rimbert M; Galéa C; Tiollier J; Calvo F
Cancer Immunol Immunother; 2010 Oct; 59(10):1521-30. PubMed ID: 20563721
[TBL] [Abstract][Full Text] [Related]
60. Phase I evaluation of therapy with four schedules of 5-fluorouracil by continuous infusion combined with recombinant interferon alpha.
Greenblatt MS; Mangalik A; Ferguson J; Elias L
Clin Cancer Res; 1995 Jun; 1(6):615-20. PubMed ID: 9816023
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
